Microdosing Tirzepatide (GLP-1) for MCAS: A Hypothesis Worth Testing — But Not Yet Proven
Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Few topics in the MCAS world have generated as much excitement — and as much premature confidence — as the idea of using GLP-1 receptor agonists at sub-therapeutic doses to calm mast cell activation. Social